cessful hematologic reconstitution following allogeneic BMT for SAA complicating orthotopic liver transplantation for fulminant liver failure. 4,5 In both reported cases, Severe aplastic anemia (SAA) is a frequent complication of orthotopic liver transplantation for non-typeable immunosuppression to prevent liver graft rejection and graft-versus-host disease (GVHD) was achieved with viral hepatitis. Allogeneic bone marrow transplantation (BMT) may successfully reconstitute hematopoiesis but cyclosporin A (CsA) and prednisone. Tacrolimus (FK506) is an immunosuppressant isolated the optimal conditioning regimen and graft-versus-host disease (GVHD) prophylaxis in such patients are from Streptomyces tsukubaensis 6 which has been demonstrated in vitro to be approximately 10 to 100 times more unknown. Allogeneic BMT was undertaken in an 8-year-old male patient who developed SAA 6 weeks after potent than CsA. 7 In recent studies, FK506 has been shown to be associated with significantly fewer episodes of refraccadaveric orthotopic liver transplantation for fulminant hepatic failure secondary to presumed non-typeable tory liver graft rejection but was accompanied by more adverse effects, resulting in equivalent patient and graft surviral hepatitis. The preparative regimen for his HLA genotypically identical sibling BMT consisted of cytoxan vival, when compared to CsA. 8,9 The efficacy of FK506 as an immunosuppressant in allogeneic BMT has been and anti-thymocyte globulin. Tacrolimus (FK506) and prednisone, used to prevent liver graft rejection, were explored in animal models. 10-12 FK506 has also been shown to prevent GVHD after histocompatible BMT in clinical supplemented with methotrexate on post-BMT days, 1, 3, 6 and 11 for GVHD prophylaxis. Engraftment propilot trials 13,14 and a recent multicenter adult study, 15 and has been used successfully in the treatment of steroid resistceeded promptly and without complications. Transfusion dependence resolved 6 weeks after BMT. The ant GVHD. 16, 17, 18 There is no published experience on the use of FK506 as GVHD prophylaxis in children undergoing patient is alive and well 1 year after his BMT on FK506 and prednisone without any signs of GVHD or liver allo-BMT. Here we report a pediatric patient with SAA following allograft rejection. This case is the first demonstration of the feasibility of continuing FK506 used for prevenliver transplantation for fulminant hepatic failure who was successfully treated with an allogeneic sibling BMT using tion of liver graft rejection as GVHD prophylaxis for allogeneic BMT.
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Here we report a pediatric patient with SAA following allograft rejection. This case is the first demonstration of the feasibility of continuing FK506 used for prevenliver transplantation for fulminant hepatic failure who was successfully treated with an allogeneic sibling BMT using tion of liver graft rejection as GVHD prophylaxis for allogeneic BMT.
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Case report
Severe aplastic anemia (SAA) complicates one third of
The patient (UPN 1269) was a previously healthy 8-yearpediatric cases of orthotopic liver transplantation for fulold male who presented in April 1995 with a short history minant liver failure following non-A, non-B and non-C of abdominal pain. He was diagnosed with hepatitis hepatitis.
1,2 In this setting SAA is associated with a high (AST = 1376 U/l, ALT = 1406 U/l, total bilirubin rate of mortality 1,2 and therapeutic immunosuppression = 14.1 mg/dl, direct bilirubin = 11.1 mg/dl) which proresults in hematologic improvement in less than half of the gressed to fulminant liver failure with severe coagulopathy patients. 1 The treatment of choice in pediatric patients with that could only be controlled with plasmapheresis. He idiopathic SAA is HLA-identical sibling bone marrow developed grade IV encephalopathy despite maximal meditransplantation (BMT).
3 Recent case reports also show succal therapy. Serologies for hepatitis A, B and C were negative as were cultures for CMV and adenovirus. Parvovirus titers and EBV VCA were also negative. Wilson's disease The white blood cell (WBC) count and the absolute neutroLevels were measured by high performance liquid chromatography (HPLC) on the days indicated in the graph.
phil count (ANC) at diagnosis were 1800 cells/mm 3 and 1200 cells/mm 3 , respectively. His hemoglobin at diagnosis was 6.9 gm/dl, his platelet count was 10 000 cells/mm 3 and he became packed red blood cell (PRBC) and platelet transInfectious prophylaxis consisted of: IVIG (Gammimmune; Miles/Cutter) at 500 mg/kg q week, day fusion dependent.
A bone marrow biopsy showed normal maturation but −7 to day +120, gut decontamination with vancopolymixin two capsules three times a day day −7 to day +23, acyclovir marked hypoplasia of all three lineages with 5% cellularity. Cytogenetic analysis showed a normal male karyotype (46, (Burroughs Wellcome) 500 mg/m 2 , i.v. three times a day, day −5 to day +27, which was replaced by ganciclovir XY). A diagnosis of severe aplastic anemia was made. Aplastic anemia only transiently responded to a 6 week (Roche Laboratories, Nutley, NJ, USA) 6 mg/kg i.v. three times/week, day +28 to day +120, fluconazole (Pfizer Labs, course of G-CSF at 10 g/kg (Neupogen; Amgen, Thousand Oaks, CA, USA) and IVIG (Gammimmune; New York, NY, USA) 200 mg p.o. daily, pentamidine 4 mg/kg days 14 and 28, which was replaced by Miles/Cutter, West Haven, CT, USA). HLA typing revealed that his 10-year-old brother was histocompatible trimethoprim/sulfamethoxazole 4 mg/kg twice a day three times/week thereafter. In addition, piperacillin and gentaat the HLA-A, -B, -DQ and -DR loci. Both the patient and the donor were positive for CMV, HSV and VZV by serolmicin were administered for an isolated temperature spike occurring on day −4, and were discontinued after stable ogy. The patient, but not the donor, was positive for IgG antibodies directed against hepatitis A and EBV, while both hematologic engraftment on day +23.
Complications from BMT included: (1) mucositis requirwere negative for IgM antibodies against hepatitis A and HHV-6 DNA as assayed by the polymerase chain reaction.
ing caloric supplementation in the form of parenteral nutrition for 18 days; (2) a transient episode of SIADH The patient was also negative for hepatitis B surface antigen and hepatitis C antibody. The interpretation of the during the administration of cyclophosphamide that resolved with careful fluid management; (3) hypertension, patient's viral titers was difficult because he had received a liver graft from a CMV-positive donor and IVIG as well successfully treated with nifedipine. Renal function remained within normal limits with a peak serum creatinine as CMV immunoglobulin. Nineteen weeks after liver transplantation and 13 weeks after onset of pancytopenia, the of 0.8 mg/dl on day +23 (baseline on day −8 0.6 mg/dl). His liver enzymes normalized during transplant with a tranpatient underwent allogeneic BMT.
Conditioning for transplantation consisted of cyclophossient rise in his AST to 78 U/l (normal range 2-40 U/l) and ALT to 207 U/l (normal range 3-30 U/l), respectively on phamide 1500 mg/m 2 /day i.v. for 4 days (days −5 to −2) and horse anti-thymocyte globulin (ATG, Upjohn, Kalamaday +22. He had signs of hematologic engraftment on day +14. The last PLT transfusion was on day +17 and the ANC zoo, MI, USA) 30 mg/kg/day for 3 days (days −4, −3 and −2). On day zero he received the bone marrow reached a level of Ͼ500 cells/mm 3 on day +20 post-BMT. Gut recontamination was started on day +23 without inci-(3.11 × 10 8 WBC/kg or 0.21 × 10 8 mononuclear cells/kg) from his fully matched brother. GVHD prophylaxis condent. He was discharged from the transplant unit on day +27 without any signs of GVHD on immunosuppression of sisted of methylprednisolone 0.3 mg/kg i.v. every morning (changed to prednisone 10 mg p.o. every morning, or FK506 2 mg p.o. every morning and 1 mg p.o. every evening (0.12 mg/kg/day) and prednisone 10 mg p.o. every 0.4 mg/kg, on day +24 post-BMT), MTX (Lederle Laboratories, Wayne, NJ, USA), given at reduced doses to minimmorning. His last PRBC transfusion was on day +42. His post-BMT course was complicated by a single 48 h ize the potential risk for liver damage (10 mg/m 2 on days +1 and +3, 5 mg/m 2 on days +6 and +11) and FK506, conreadmission for fever occurring shortly after discharge.
Evaluation 12 months following BMT shows: tinued as per pre-transplant schedule for graft rejection at 5 mg (0.2 mg/kg) p.o. twice a day and adjusted according WBC = 12 700 cells/mm 3 , ANC = 9400 cells/mm 3 , Hgb = 10.6 g/dl, PLT = 364 000 cells/mm 3 . The patient remains to measured levels with a target range of 10-15 ng/ml. Target range was achieved with lower than pre-BMT daily well without signs of liver rejection or GVHD on FK506 (levels are maintained in the range of 10-15 ng/ml) and doses of FK506 and few dose adjustments (Figure 1 ). prednisone 10 mg p.o. daily. Anti-hypertensive medications Note added in proof were successfully discontinued on day +90 post-BMT.
More than 1 year after BMT the patient developed intermittent bloody diarrhea. Biopsies of liver and gut were negative for GVHD. A thorough workup resulted in the diag- allogeneic BMT for malignancy. [13] [14] [15] [16] Data on the use of FK506 for GVHD prophylaxis in children has not been published to date.
References In this paper we describe the first successful allogeneic BMT for SAA after liver transplantation for acute non- Fay et al. 15 Despite these adjustments, our patient showed
